Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Copper Cu 64 dotatate

FDA approved · Rx

Radioactive PET imaging agent

Also known as: Detectnet, Copper dotatate Cu-64, Copper 64-DOTA-tate, detectnet, Copper oxodotreotide cu-64, 64cu-dotatate, 64Cu-DOTA-TATE

Evidence score

91/ 100

Strong evidence

Strong, human-grade evidence

Regulatory standing. FDA-approved prescription medicine
Human trials. Backed by controlled human studies
Registered human trials. 16 registered studies on ClinicalTrials.gov, most advanced Phase 4
2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Copper Cu 64 dotatate, sold as Detectnet, is a radioactive diagnostic agent made of a somatostatin analog peptide (octreotate) linked to a chelator holding the positron-emitting isotope copper-64. It binds to somatostatin receptors, which are found at high levels on many neuroendocrine tumor cells, allowing those tumors to be seen on a PET scan.

What the evidence shows

Automatic summaryHuman trials

It is FDA approved for PET imaging to help locate somatostatin receptor-positive neuroendocrine tumors in adults. It is a diagnostic tool rather than a treatment, and registered human trials have reached Phase 4.

Key facts

Molecular formula

C65H88CuN14O19S2

Molecular weight

1497.5 g/mol

FDA approval

Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

16registered studies

Phase 4most advanced phase

4completed (sample)

7recruiting (sample)

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Phase 3RecruitingNCT06878664

Spanish Series of Patients Treated With the Radionuclide Lutetium177

RecruitingNCT04949282

64Cu-DOTATATE PET-CT-skanning and Infective Endocarditis.

CompletedNCT05432427

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Phase 2UnknownNCT05709171

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

2papers referencing Copper Cu 64 dotatate

Production of the PET radionuclide 61Cu via the 62Ni(p,2n)61Cu nuclear reaction.

EJNMMI Radiopharm Chem2024

Copper Cu 64 Dotatate

2006

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.